Der Schmerz

, Volume 32, Issue 2, pp 90–98 | Cite as

Symptomlinderung durch Tumortherapie?

Eine systematische Übersicht über onkologische Therapiestudien
Übersichten

Zusammenfassung

Hintergrund

Bei inkurabel erkrankten Krebspatienten wird die medikamentöse Tumortherapie zumeist mit dem Ziel einer längeren Überlebenszeit bei zugleich möglichst geringer Toxizität und tolerabler Lebensqualität unter der Therapie eingesetzt. Unklar ist, inwieweit und mit welchem Erfolg die medikamentöse Tumortherapie zu einer gezielten Verbesserung von vorbestehenden Schmerzen und einer bereits kompromittierten Lebensqualität eingesetzt werden kann.

Methodik

Daher wurde ein „systematic review“ onkologischer Therapiestudien (PubMed) durchgeführt. Es wurden ausschließlich Studien ausgewählt und deskriptiv ausgewertet, die schmerzlindernde bzw. lebensqualitätsverbessernde Effekte einer medikamentösen Tumortherapie als primären Studienendpunkt auswiesen.

Ergebnisse

Von den 2229 mithilfe eines pilotierten Such-Strings identifizierten Abstracts erfüllten nach Durchsicht lediglich 13 Studien die Einschlusskriterien. Von diesen zeigten 10 Studien eine Verbesserung von Lebensqualitätsparametern durch den Einsatz systemischer Tumortherapien.

Diskussion

Nur wenige Studien fokussierten primär auf die Verbesserung lebensqualitätsbezogener Parameter – obwohl dies für nicht wenige inkurabel und fortgeschritten erkrankte Krebspatienten das vorrangige Therapieziel darstellt. Die Studienergebnisse ermutigen dazu, symptom- und lebensqualitätsbezogene Daten regelmäßig in klinischen Studien zu berücksichtigen und das Potenzial der onkologischen Tumortherapie für palliativmedizinisch relevante Zielsetzungen der Schmerz- und Symptomlinderung expliziter zu adressieren.

Schlüsselwörter

Schmerzen Lebensqualität „Systematic review“ Tumortherapie Studien 

Anticancer therapy for symptom relief?

A systematic review of clinical trials in oncology

Abstract

Background

When patients suffer from incurable cancer, drug-based, systemic anticancer therapy is usually used with the aim of longer survival, while minimizing toxicity and ensuring a tolerable quality of life. It is unclear to what extent and with what degree of success systemic tumor therapy can be used to specifically improve pre-existing pain and an already compromised quality of life (QoL).

Methods

Therefore, a systematic review of oncological therapy studies (PubMed) was conducted. Only studies that identified the pain-relieving and QoL-enhancing effects of systemic anticancer therapy as the primary endpoint were selected and evaluated descriptively.

Results

Of the 2229 abstracts identified using a piloted search string, only 13 studies met the inclusion criteria. Of these, 10 studies showed an improvement in QoL-parameters through the use of systemic tumor therapies.

Discussion

Only a few studies focused primarily on the improvement of parameters related to quality of life—although this is the primary therapeutic goal for many patients suffering from incurable and advanced cancer. The study results encourage regular inclusion of symptom- and QoL-related data in clinical studies and to more explicitly address the potential of systemic anticancer therapy in relieving pain and other symptoms, thereby supporting the goals of palliative care.

Keywords

Pain Quality of life Systematic review Tumor therapy Studies 

Notes

Danksagung

Das methodische Konzept dieser Übersichtsarbeit wurde in enger Zusammenarbeit mit dem Institut für Medizinische Statistik der Universität Göttingen (Prof. Dr. T. Friede, PD Dr. S. Straube) erstellt – für diese Unterstützung möchten die Autoren herzlich danken.

Einhaltung ethischer Richtlinien

Interessenkonflikt

B. Alt-Epping, A.-L. Haas, M. Jansky und F. Nauck geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376CrossRefPubMedGoogle Scholar
  2. 2.
    Alt-Epping B, Jung W, Nauck F (2007) Symptomkontrollierende Effekte der Chemotherapie. Onkologe 13:619–624CrossRefGoogle Scholar
  3. 3.
    Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, Milroy R, Maughan TS, Falk SJ, Bond MG et al (2000) Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Br J Cancer 83:447–453CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Anderson J, Al-Ali G, Wirth M, Gual JB, Gomez Veiga F, Colli E, van der Meulen E, Persson B‑E (2013) Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233). Urol Int 90:321–328CrossRefPubMedGoogle Scholar
  5. 5.
    Alt-Epping B, Seidel W, Vogt J, Mehnert A, Thomas M, van Oorschot B, Wolff H, Schliephake H, Canis M, Dröge LH, Nauck F, Lordick F, Arbeitsgemeinschaft Palliativmedizin (APM) of the German Cancer Society (DKG) (2016) Symptoms and needs of head and neck cancer patients at diagnosis of incurability – prevalences, clinical implications and feasibility of a prospective longitudinal multicenter cohort study. Oncol Res Treat 39:186–191CrossRefPubMedGoogle Scholar
  6. 6.
    Baka S, Ashcroft L, Anderson H, Lind M, Burt P, Stout R, Dowd I, Smith D, Lorigan P, Thatcher N (2005) Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status〈/= 70) and advanced non-small-cell lung cancer. J Clin Oncol 23:2136–2144CrossRefPubMedGoogle Scholar
  7. 7.
    Basch E, Abernethy AP, Mullins CD, Reeve BB, Smith ML, Coons SJ, Sloan J, Wenzel K, Chauhan C, Eppard W et al (2012) Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 30:4249–4255CrossRefPubMedGoogle Scholar
  8. 8.
    Bausewein C, Daveson BA, Currow DC, Downing J, Deliens L, Radbruch L, Defilippi K, Lopes Ferreira P, Costantini M, Harding R, Higginson IJ (2016) EAPC White Paper on outcome measurement in palliative care: improving practice, attaining outcomes and delivering quality services – recommendations from the European Association for Palliative Care (EAPC) Task Force on Outcome Measurement. Palliat Med 30:6–22CrossRefPubMedGoogle Scholar
  9. 9.
    Belani CP, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P et al (2006) Effect of chemotherapy for advanced non-small cell lung cancer on patients’ quality of life. A randomized controlled trial. Lung Cancer 53:231–239CrossRefPubMedGoogle Scholar
  10. 10.
    Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 30:635–642CrossRefGoogle Scholar
  11. 11.
    Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, Saletti P et al (2008) Clinical benefit and quality of life in patients with advanced pancreatic cancer  receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial – SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol 26:3695–3701CrossRefPubMedGoogle Scholar
  12. 12.
    Bezjak A, Tu D, Bacon M, Osoba D, Zee B, Stuart G, Roy J‑A, Piccart M, Eisenhauer E (2004) Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol 22:4595–4603CrossRefPubMedGoogle Scholar
  13. 13.
    Biesma B, Wymenga AN, Vincent A, Dalesio O, Smit HJ, Stigt JA, Smit EF, van Felius CL, van Putten JW, Slaets JP, Groen HJ (2011) Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study. Ann Oncol 22:1520–1527CrossRefPubMedGoogle Scholar
  14. 14.
    Bonnetain F, Bouche O, Conroy T, Arveux P, Raoul J‑L, Giovannini M, Etienne PL, Mitry E, Seitz J‑F, Rougier P et al (2005) Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in a randomized phase II trial in digestive oncology. Gastroenterol Clin Biol 29:1113–1124CrossRefPubMedGoogle Scholar
  15. 15.
    Bördlein-Wahl I, Hilpert F, Kohlmann T (2009) Therapiebeurteilung aus Patientensicht – PROs (Patient Reported Outcomes). Onkologie 32(suppl 1):18–20CrossRefPubMedGoogle Scholar
  16. 16.
    Bottomley A, Biganzoli L, Cufer T, Coleman RE, Coens C, Efficace F, Calvert HA, Gamucci T, Twelves C, Fargeot P, Piccart M (2004) Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study. J Clin Oncol 22:2576–2586CrossRefPubMedGoogle Scholar
  17. 17.
    Buccheri G, Ferrigno D, Tamburini M (1996) Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32:1135–1141CrossRefGoogle Scholar
  18. 18.
    Bukowski R, Cella D, Gondek K, Escudier B (2007) Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 30:220–227CrossRefPubMedGoogle Scholar
  19. 19.
    Burris H, Storniolo AM (1997) Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5‑fluorouracil. Eur J Cancer 33(Suppl 1):18–22CrossRefGoogle Scholar
  20. 20.
    Cassier PA, Chabaud S, Trillet-Lenoir V, Peaud P‑Y, Tigaud J‑D, Cure H, Orfeuvre H, Salles B, Martin C, Jacquin J‑P et al (2008) A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel  in metastatic breast cancer: results of the ERASME 3 study. Breast Cancer Res Treat 109:343–350CrossRefPubMedGoogle Scholar
  21. 21.
    Castellano D, del Muro XG, Perez-Gracia JL, Gonzalez-Larriba JL, Abrio MV, Ruiz MA, Pardo A, Guzman C, Cerezo SD, Grande E (2009) Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. Ann Oncol 20:1803–1812CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P (1995) Reliability and validity of the functional assessment of cancer therapy – lung (FACT-L) quality of life instrument. Lung Cancer 12:199–220CrossRefPubMedGoogle Scholar
  23. 23.
    Chang VT, Hwang SS, Feuerman M, Kasimis BS (2000) Symptom and quality of life survey of medical oncology patients at a veterans affairs medical center: a role for symptom assessment. Cancer 88:1175–1183CrossRefPubMedGoogle Scholar
  24. 24.
    Colombo N, Mangili G, Mammoliti S, Kalling M, Tholander B, Sternas L, Buzenet G, Chamberlain D (2012) A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol 125:42–47CrossRefPubMedGoogle Scholar
  25. 25.
    Cooley ME (2000) Symptoms in adults with lung cancer: a systematic research review. J Pain Symptom Manage 19:137–153CrossRefPubMedGoogle Scholar
  26. 26.
    Corey-Lisle PK, Peck R, Mukhopadhyay P, Orsini L, Safikhani S, Bell JA, Hortobagyi G, Roche H, Conte P, Revicki DA (2012) Q‑TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer. Cancer 118:461–468CrossRefPubMedGoogle Scholar
  27. 27.
    Degner LF, Sloan JA (1995) Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. J Pain Symptom Manage 10:423–431CrossRefPubMedGoogle Scholar
  28. 28.
    Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, Kim YH, Heald PW, Bacha P, Nichols J, Liepa A (2002) Quality-of-life improvements in cutaneous T‑cell lymphoma patients treated with denileukin diftitox (ONTAK). Clin Lymphoma 2:222–228CrossRefPubMedGoogle Scholar
  29. 29.
    Eckhardt SG, De Porre P, Smith D, Maurel J, Steward WP, Bouche O, van de Velde H, Michiels B, Bugat R (2009) Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer. J Pain Symptom Manage 37:135–143CrossRefPubMedGoogle Scholar
  30. 30.
    Fishman B, Pasternak S, Wallenstein SL, Houde RW, Holland JC, Foley KM (1987) The memorial pain assessment card. A valid instrument for the evaluation of cancer pain. Cancer 60:1151–1158CrossRefPubMedGoogle Scholar
  31. 31.
    Gebbia V, Lorusso V, Galetta D, Caruso MM, Palomba G, Riccardi F, Borsellino N, Carrozza F, Leo S, Ferrau F et al (2010) First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale. Lung Cancer 69:218–224CrossRefPubMedGoogle Scholar
  32. 32.
    Gillick MR (2005) Rethinking the central dogma of palliative care. J Palliat Med 8:909–913CrossRefPubMedGoogle Scholar
  33. 33.
    Girling DJ (1996) Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 348:563–566CrossRefPubMedGoogle Scholar
  34. 34.
    Glimelius B, Hoffman K, Graf W, Pahlman L, Sjoden PO (1994) Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Cancer 73:556–562CrossRefPubMedGoogle Scholar
  35. 35.
    Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne T, Svensson C (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593–600CrossRefPubMedGoogle Scholar
  36. 36.
    Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163–168CrossRefPubMedGoogle Scholar
  37. 37.
    Gotlieb WH, Amant F, Advani S, Goswami C, Hirte H, Provencher D, Somani N, Yamada SD, Tamby J‑F, Vergote I (2012) Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 13:154–162CrossRefPubMedGoogle Scholar
  38. 38.
    Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul J‑L, Boige V et al (2013) Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 31:23–29CrossRefPubMedGoogle Scholar
  39. 39.
    Gronberg BH, Bremnes RM, Flotten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollali T et al (2009) Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27:3217–3224CrossRefPubMedGoogle Scholar
  40. 40.
    Higginson IJ, Gomes B, Calanzani N, Gao W, Bausewein C, Daveson BA, Deliens L, Ferreira PL, Toscani F, Gysels M et al (2014) Priorities for treatment, care and information if faced with serious illness: a comparative population-based survey in seven European countries. Palliat Med 28:101–110CrossRefPubMedGoogle Scholar
  41. 41.
    Hirsh V, Cadranel J, Cong XJ, Fairclough D, Finnern HW, Lorence RM, Miller VA, Palmer M, Yang JC-H (2013) Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol 8:229–237CrossRefPubMedGoogle Scholar
  42. 42.
    Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Hrsg) (2014) Kuration vs. Palliation: Versuch einer Begriffsklärung. IQWiG-Berichte Nr. 212. IQWiG, KölnGoogle Scholar
  43. 43.
    Joly F, Vardy J, Pintilie M, Tannock IF (2007) Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol 18:1935–1942CrossRefPubMedGoogle Scholar
  44. 44.
    Kaasa S, Mastekaasa A, Stokke I, Naess S (1988) Validation of a quality of life questionnaire for use in clinical trials for treatment of patients with inoperable lung cancer. Eur J Cancer Clin Oncol 24:691–701CrossRefPubMedGoogle Scholar
  45. 45.
    Khan K, Kunz R, Kleijnen J, Antes G (2011) Systematic reviews, 2. Aufl. Hodder Arnold, LondonGoogle Scholar
  46. 46.
    Levy V, Porcher R, Delabarre F, Leporrier M, Cazin B, Chevret S (2001) Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis. J Clin Epidemiol 54:747–754CrossRefPubMedGoogle Scholar
  47. 47.
    Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN et al (2012) Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the. Lancet Oncol 13:1210–1217CrossRefPubMedGoogle Scholar
  48. 48.
    McQuellon RP, Thaler HT, Cella D, Moore DH (2006) Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 101:296–304CrossRefPubMedGoogle Scholar
  49. 49.
    Melzack R (1975) The McGill Pain Questionnaire: major properties and scoring methods. Pain 1:277–299CrossRefPubMedGoogle Scholar
  50. 50.
    Meyer R (2015) Palliative Krebsbehandlung: Chemotherapie erhöht Lebensqualität häufig nicht. Dtsch Arztebl Int 112:A–1576/B–1312/C–1282Google Scholar
  51. 51.
    Oncology Group (2016) Eastern Cooperative Oncology Group (ECOG) Performance Status. http://ecog-acrin.org/resources/ecog-performance-status;. Zugegriffen: 11. Jan. 2016Google Scholar
  52. 52.
    Osoba D, Tannock IF, Ernst DS, Neville AJ (1999) Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 17:1654–1663CrossRefPubMedGoogle Scholar
  53. 53.
    Osoba D, Slamon DJ, Burchmore M, Murphy M (2002) Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 20:3106–3113CrossRefPubMedGoogle Scholar
  54. 54.
    Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Coyle N, Smart-Curley T, Kemeny N, Norton L, Hoskins W (1994) Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 3:183–189CrossRefPubMedGoogle Scholar
  55. 55.
    Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, Garrido MM, Reid MC, Berlin DA, Adelson KB et al (2015) Chemotherapy use, performance status, and quality of life at the end of life. Jama Oncol 1:778–784CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (2015) Krebs in Deutschland 2011/2012. 10. Ausgabe. Robert Koch-Institut, Berlin (http://www.gekid.de/Doc/krebs_in_deutschland_2015.pdf Zugriff 20.08.2017)Google Scholar
  57. 57.
    Rock EP, Scott JA, Kennedy DL, Sridhara R, Pazdur R, Burke LB (2007) Challenges to use of health-related quality of life for food and drug administration approval of anticancer products. J Natl Cancer Inst Monographs 37:27–30CrossRefGoogle Scholar
  58. 58.
    Schandelmaier S, Conen K, von Elm E, You JJ, Blumle A, Tomonaga Y, Saccilotto R, Amstutz A, Bengough T, Meerpohl JJ et al (2015) Planning and reporting of quality-of-life outcomes in cancer trials. Ann Oncol 26:1966–1973CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K, SIGN Study Group (2006) Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 17:401–409CrossRefPubMedGoogle Scholar
  60. 60.
    Silvestri G, Pritchard R, Welch HG (1998) Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 317:771–775CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Svensson H, Einbeigi Z, Johansson H, Hatschek T, Brandberg Y (2010) Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine). Breast Cancer Res Treat 123:785–793CrossRefPubMedGoogle Scholar
  62. 62.
    Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764CrossRefPubMedGoogle Scholar
  63. 63.
    Vansteenkiste JF, Vandebroek JE, Nackaerts KL, Weynants P, Valcke YJ, Verresen DA, Devogelaere RC, Marien SA, Humblet YP, Dams NL (2001) Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 12:1221–1230CrossRefPubMedGoogle Scholar
  64. 64.
    Vinante O, Bari M, Segati R, Azzarello G, Sampognaro E, Rosetti F, Pappagallo GL (1993) The combination of mitomycin, vinblastine and cisplatin is active in the palliation of stage IIIB-IV non-small-cell lung cancer. Oncology 50:1–4CrossRefPubMedGoogle Scholar
  65. 65.
    Voogt E, van der Heide A, Rietjens J et al (2005) Attitudes of patients with incurable cancer toward medical treatment in the last phase of life. J Clin Oncol 23(9):2012–2019CrossRefPubMedGoogle Scholar
  66. 66.
    Weingartner V, Dargatz N, Weber C, Mueller D, Stock S, Voltz R, Gaertner J (2016) Patient reported outcomes in randomized controlled cancer trials in advanced disease: a structured literature review. Expert Rev Clin Pharmacol 9:821–829CrossRefPubMedGoogle Scholar
  67. 67.
    Wilkie DJ, Savedra MC, Holzemer WL, Tesler MD, Paul SM (1990) Use of the McGill Pain Questionnaire to measure pain: a meta-analysis. Nurs Res 39:36–41CrossRefPubMedGoogle Scholar
  68. 68.
    Winkler EC, Reiter-Theil S et al (2009) Patient involvement in decisions to limit treatment: the crucial role of agreement between physician and pa-tient. J Clin Oncol 27:2225–2230CrossRefPubMedGoogle Scholar
  69. 69.
    Yang JC-H, Hirsh V, Schuler M, Yamamoto N, O’Byrne KJ, Mok TSK, Zazulina V, Shahidi M, Lungershausen J, Massey D et al (2013) Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib  or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3342–3350CrossRefPubMedGoogle Scholar
  70. 70.
    Yang S, de Souza P, Alemao E, Purvis J (2010) Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha. Br J Cancer 102:1456–1460CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Zbrozek AS, Hudes G, Levy D, Strahs A, Berkenblit A, DeMarinis R, Parasuraman S (2010) Q‑TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. Pharmacoeconomics 28:577–584CrossRefPubMedGoogle Scholar

Copyright information

© Deutsche Schmerzgesellschaft e.V. Published by Springer Medizin Verlag GmbH, ein Teil von Springer Nature - all rights reserved 2018

Authors and Affiliations

  • B. Alt-Epping
    • 1
  • A.-L. Haas
    • 2
  • M. Jansky
    • 1
  • F. Nauck
    • 1
  1. 1.Klinik für PalliativmedizinUniversitätsmedizin GöttingenGöttingenDeutschland
  2. 2.Medizinische FakultätUniversitätsmedizin GöttingenGöttingenDeutschland

Personalised recommendations